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Abstract  
While changes in SARS-CoV-2 viral load over time have been documented, detailed 
information on the impact of remdesivir and how it might alter intra-host viral evolution is 
limited. Sequential viral loads and deep sequencing of SARS-CoV-2 recovered from the upper 
respiratory tract of hospitalised children revealed that remdesivir treatment suppressed viral 
RNA levels in one patient but not in a second infected with an identical strain. Evidence of 
drug resistance to explain this difference was not found. Reduced levels of subgenomic (sg) 
RNA during treatment of the second patient, suggest an additional effect of remdesivir on viral 
replication that is independent of viral RNA levels. Haplotype reconstruction uncovered 
persistent SARS-CoV-2 variant genotypes in four patients. We conclude that these are likely 
to have arisen from within-host evolution, and not co-transmission, although superinfection 
cannot be excluded in one case. Sample-to-sample heterogeneity in the abundances of variant 
genotypes is best explained by the presence of discrete viral populations in the lung with 
incomplete population sampling in diagnostic swabs. Such compartmentalisation is well 
described in serious lung infections caused by influenza and Mycobacterium tuberculosis and 
has been associated with poor drug penetration, suboptimal treatment and drug resistance. Our 
data provide evidence that remdesivir is able to suppress SARS-CoV-2 replication in vivo but 
that its efficacy may be compromised by factors reducing penetration into the lung. Based on 
data from influenza and Mycobacterium tuberculosis lung infections we conclude that early 
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Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes Coronavirus 
Disease 2019 (COVID-19), was first identified in Wuhan, China in December 2019. On 11th 
March 2020, the WHO declared COVID-19 a global pandemic (1). Since then, an estimated 
50 million people have been infected of whom up to 2.5% have died (2). A number of studies 
have assessed nasal and oropharyngeal viral load data from longitudinally sampled SARS-
CoV-2 infected patients. Their findings reveal wide variations in viral load at presentation (3–
6). However, milder disease and clinical recovery are associated with lower and declining viral 
load respectively, pointing to its potential use as a biomarker for antiviral drug response. 
Remdesivir, an RNA-dependent-RNA polymerase (RdRp) inhibitor, has been shown in one 
large randomised clinical trial (RCT) to be effective against SARS-CoV-2, although another 
large study, showed no clinical benefit and smaller studies have shown limited or no impact on 
clinical recovery (3,7–11). Where clinical trial data are lacking or contradictory we have 
previously used deep pathogen sequencing, mutational analysis and evolutionary modelling to 
gain insight into the impact of repurposed drugs, including RdRp inhibitors similar to 
remdesivir, on serious respiratory RNA viral infections in hospitalised patients (12,13).  These 
studies have revealed drug-related mutational signatures, evidence of viral 
compartmentalisation in the lung and previously unrecognised synergy between combination 
therapies associated with changes in viral loads and improved clinical outcomes. Here we 
report the application of similar methods in a personalised-medicine-approach to investigating 
the impact of remdesivir on SARS-CoV-2 within an individual and to evaluate potential 
biomarkers that can be used to monitor clinical efficacy. The data provide further insights into 
fundamental questions of SARS-CoV-2 evolution and co-infection. 
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Results 
 
Overview of Patients 
We analysed nine hospitalised SARS-CoV-2 positive paediatric cases with a mean age at time 
of infection of 4.7 years old (range 0-14 years old), who were repeatedly sampled during the 
course of their SARS-CoV-2 infection. A summary of their clinical features is shown in Table 
1. Five patients had pre-existing co-morbidities associated with primary or secondary 
immunodeficiency (Table 1). Of the nine patients, four (A, D, G and H), of whom only H was 
known to be immunocompromised, were admitted to the Paediatric Intensive Care Unit (PICU) 
(supplementary figure 1). The remaining patients were cared for in appropriate source isolation 
and were not co-located during their SARS-CoV-2 infection (supplementary figure 1). Patients, 
A, D, and G received 8 - 10 days of remdesivir through the compassionate access programme. 
Patient A and G received 200 mg loading dose followed by 100 mg daily and Patient D received 
5mg/kg (10 mg) loading dose and 1.25 mg/kg (2.5 mg) once daily (Table 1). 
 
Viral load trajectories by cycle threshold and clinical markers of infection 
Figure 1 shows the viral polymerase chain reaction (PCR) cycle threshold (ct) values for all 
nine patients for forty days following their first positive nasopharyngeal aspirate (NPA) 
available to us. Viral RNA was measured in NPAs for all patients and/or upper airway 
secretions for those who were intubated (patients A, D, G, and H). Patients A also had a 
Bronchoalveolar lavage. In agreement with earlier studies (14), the ct values showed 
considerable day-to-day variation of between 0.16 and 14.4 cycle numbers (median 5.5 cycle 
numbers). Viral RNA continued to be detectable for 7 to over 50 days (median 16 days) 
following the first positive sample (supplementary figure 2). Of the three patients who received 
remdesivir, only patient D had total suppression of viral RNA during treatment followed by 
rebound of virus after treatment cessation (figure 1). The four ICU patients were clinically most 
All rights reserved. No reuse allowed without permission. 
perpetuity. 
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 
The copyright holder for thisthis version posted November 20, 2020. ; https://doi.org/10.1101/2020.11.18.20230599doi: medRxiv preprint 
unwell, requiring assisted ventilation. All three remdesivir-treated patients showed clinical 
improvement after starting the drug, associated with falls in temperature (all) and inflammatory 
markers (A and G) (supplementary figure 3). All three were weaned from conventional 
ventilation before the treatment course was completed with decreases in oxygen requirements. 
In patient D, a significant reversal of respiratory deterioration was noted once remdesivir was 
started; inhaled nitric oxide was stopped within 96 hours coincident with weaning from high 
frequency oscillatory to conventional ventilation. Patient D, who alone required inotropic 
support, achieved haemodynamic stability off inotropes within 5 days of starting remdesivir.  
 
Inter and intra-host phylodynamics of SARS-CoV-2 
To investigate the possibility of remdesivir resistance in patients A and G, neither of whose 
viral RNA was suppressed by remdesivir treatment (figure 1), and in patient D whose virus 
rebounded following cessation of treatment, we deep sequenced all samples as well as those 
from untreated patients for comparison. The sequencing metrics for the samples are 
summarised in Supplementary Table 1. Relative to their first available sample, there were nine 
polymorphisms identified in viruses from patients A, H and I of which five were non-
synonymous with four in the ORF1ab (nsps 1,3,4,5) and one in the Spike protein, S2 
subdomain (supplementary table 2). This latter mutation P812L in patient I is located in a T-
cell epitope (15). None of the identified SNPs were sites identified as common homoplasies or 
those known to be susceptible to Illumina sequencing error, none have been associated with 
remdesivir resistance and none other than P812L were in known or predicted immune epitopes 
(16–22). Both consensus level mutations in patient A, who received remdesivir were non-
synonymous. One was located in the nsp4 (responsible for formation of double membrane 
vesicle) and the other in nsp5 (a chymotrypsin-like protease responsible for polypeptides 
cleaving at 11 sites downstream to release nsp4-nsp16 and inhibition of interferon signalling) 
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of ORF1ab (18,23,24). Nsp5 has been shown to mediate the maturation of nsps downstream 
which is an essential part of the viral lifecycle (23); this has made it a desirable target for 
antiviral drug production (25,26). However, the nsp5 mutation P241L observed in patient A 
was not found to be in an active site. Virus from patient D, which rebounded following 
cessation of remdesivir treatment, was genetically identical to pre-treatment virus.  
Patients H and I who did not receive remdesivir, also had consensus level sequence changes 
(supplementary table 2). Only one of four mutations for patient H was non-synonymous and 
this was in nsp3 (a papain-like protease) in ORF1ab. Two of three mutations in patient I were 
non-synonymous, one in nsp1 (responsible for cellular mRNA degradation and inhibition of 
interferon signalling) in ORF1ab and the other upstream of the furin cleavage site and the S2’ 
cleavage site in the spike protein (27,28). This Spike mutation although not predicted to alter 
structure, does lie within a known CD4 epitope although it is not known whether it would 
abrogate T cell binding  (supplementary figure 4) (15). Patient E was negative for SARS-CoV-
2 on consecutive samples obtained on days 16 and 22. Virus detected again at days 31 and 35 
was identical to all other sequences from this patient. We observed changes in the consensus 
sequences between different samples from patients A, H and I. Sequences A at time point 6, 7, 
and 8 were identical to those of samples sequenced from patient D as depicted in Figure 2 A. 
No evidence of laboratory contamination to explain the identity between A and D sequences 
was found, with samples from these patients being sequenced in separate batches on separate 
days.  
 
No mutagenic signature identified for remdesivir 
Ribavirin and favipiravir, which like remdesivir are nucleoside analogues, have been shown to 
inhibit RdRps at higher drug concentrations while at lower concentrations they appear to drive 
the accumulation of mutations, in particular C to T and A to G transversions (13,29). The 
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mutagenic effect is associated with loss of infectivity and with an effective clinical response 
(29). In vitro studies have not shown lethal mutagenesis to be a feature of remdesivir (30,31). 
However, to exclude non-lethal mutagenesis as a possible explanation for continuing high viral 
RNAs despite remdesivir treatment, we compared the mutational burden and patterns of 
transitions and transversions in treated and untreated patients. In accordance with current 
understanding of its mode of action, we found neither an increased mutational burden in 
remdesivir-treated patients nor any evidence of associated mutational signature (supplementary 
figure 5 and supplementary figure 6). We found no evidence that the proportion of transitions 
and transversions distribution of mutation was dependent on the treatment (Fisher t-test, 
p=0.13). 
 
Measurement of subgenomic RNA 
To determine whether, despite stable viral ct values, remdesivir treatment may have inhibited 
viral replication we analysed subgenomic RNA (sgRNA) detected by the genome sequencing 
using the program Periscope (32). sgRNA derives from negative stranded RNA intermediates 
generated during SARS-CoV-2 replication (33,34). SARS-CoV-2 elaborates ten canonical 
transcripts, although ORF 10 sgRNA has never been detected (32,35–37). To optimise 
recovery, we excluded genomes with <90% coverage and <100 mean read depth (MRD). 
Stacked bar-plots of the frequency of sgRNA reads per 100,000 mapped reads (sgRPHT) for 
each gene and corresponding ct values for each patient are compared in figure 3A. Unlike 
previous reports, no correlation was found between sgRPHT and ct-values (supplementary 
figure 7A) (35). We have excluded patient D from the comparative analysis below as their 
virus was suppressed below the limit of detection during remdesivir treatment, which does not 
permit us to measure sgRPHT by the current technique. sgRNA levels in samples taken during 
remdesivir treatment for patients A and G were lower than in samples off treatment (Mann-
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Whitney-Wilcoxon Test p = 0.05) (figure 3B). Samples 6,7 and 8 in patient A had a mean viral 
ct values of 28.7 (range 28.24 – 29.02) with barely detectable sgRNA despite high MRDs 
(3402-6297). sgRNA was detected in all other samples with ct values <35 bar two. A similar 
tendency towards significance of remdesivir treatment on levels of sgRPHT was shown across 
all patients over all time points (Mann-Whitney-Wilcoxon Test p= 0.059) (supplementary 
figure 7 B).  
 
Evidence of mixed infection 
We observed changes in the consensus sequences at different timepoints in patients A, H and 
I as depicted in figure 2A. To examine this and the identical sequences from patients D and A 
further, we analysed minor variant alleles (MVAs) as outlined in the methods. A complete list 
of identified polymorphisms for each sample, and corresponding frequency and read support, 
can be found in supplementary table 3. Patients A, B, H, and I had well supported MVAs which 
varied in frequency over time (supplementary figure 8). MVAs in other patients occurred for 
the most part on a single occasion or at levels <20% with poor read support. To resolve possible 
mixed infections within each sample, we used the haplotype reconstruction method HaROLD 
(38). HaROLD identified three haplotypes for patient A, four for patient H, two for patient I, 
two in patient B with one in all other patients. All identified haplotypes are labelled as 
Hap_[number]_[Patient][Time]. Haplotypes clustered phylogenetically by patient other than 
for Hap1_A, found at the root of the clade from patient A, which was identical to viral 
sequences from patient D (figure 2B). Haplotype-defining sites are indicated along branches, 
the corresponding read support for each of these is identified in supplementary table 3. The 
abundance of each haplotype over time is shown for patients A, B, H, and I (figure 4 A). We 
observed no obvious pattern of haplotype change in any of the patients, with sample-to-sample 
variation in viral loads and haplotype abundance occurring particularly in patients A and H.  
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Since independent SARS-CoV-2 lineages that differ by one or two SNPs are frequently seen 
in the UK, we first determined whether the haplotypes within patients A, H, I, and B were 
likely to represent co-infections with different viruses (39). Using Local Lineage and 
Monophyly Assessment (LLAMA) (40), we identified the lineage in the global alignment on 
COVID-19 Genomics UK (COG-UK) (41) consortium nearest to each haplotype. The local 
trees identified by LLAMA are shown in supplementary figure 9, with a single local tree 
representing each of the observed lineages. Comparison of haplotypes in patients A, H, and I 
with global sequences confirmed that haplotypes Hap1_A, Hap2_A, Hap3_H and Hap1_I were 
circulating as independent lineages in the UK and globally as were the single genotypes from 
patients C, E, and F (Supplementary Figure 9). However, haplotypes Hap3_A, Hap1/2_B, 
Hap1/2_H and Hap2_I as well as the virus from patient G were not represented among 61740 
global sequences available on GISAID (42). This may reflect incomplete population sampling 
or the recent emergence of new lineages. Alternatively, it is possible that some haplotypes e.g. 
Hap3_A, Hap1/2_H and Hap2_I are not currently freely circulating in the population and 
possibly that the mutations they carry are deleterious as has been postulated for influenza(43). 
The close clustering between each of the non-circulating viruses with other haplotypes in their 
cognate hosts supports the possibility of within-host evolution (supplementary figure 9).  
 
An alternative explanation, given that patients A, B, H, and I apparently had mixed populations 
on first testing or soon after, is that these patients were co-infected with multiple viruses as has 
previously been suggested (44). Analysis of a separate dataset of 318 sequences collected in 
Glasgow between 28/02/2020 and 29/04/2020 found no relationship between the number of 
shared MVAs and the consensus sequence pairwise distance, suggesting that shared diversity 
is not commonly due to co-transmission in contrast to earlier work (supplementary figure 10) 
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(44). As proof of concept we reconstructed haplotypes for four of the sequences, each of which 
had optimal MVA distribution (as detailed in the methods) for HaROLD analysis. We found 
between two and three closely related haplotypes for each patient clustered by patient as 
described for samples A, B, H, and I (supplementary figure 10). As was the case for A, H and 
I, only one haplotype per patient was represented among freely circulating viruses in global 
sequence alignment provided by COG-UK, reinforcing the likelihood that the variant 
genotypes had arisen within each host.  
 
A possible exception to this conclusion was patient A. It is conceivable that haplotype Hap1_A, 
which is identical to the viral sequence from patient D, could have resulted from superinfection. 
Patients A and D were co-located in the Intensive Care Unit (ICU) (Supplementary Figure 1). 
Haplotype Hap1_A was not identified in the sample taken from patient A before their transfer 
to the ICU but was detected approximately 28 hours later in a sample taken two hours before 
starting remdesivir (Figure 4 B). Were superinfection the explanation, the appearance of 
Hap2_A could be explained either by recombination between Hap3_A and Hap1_D following 
transfer of patient A to the ICU or by within-host mutation of Hap 3_A. However, no other 
healthcare associated transmissions were reported in the ICU and local epidemiological 
investigation made it unlikely. Moreover, in view of the rapid appearance of Hap1_A following 
transfer to ICU and the variation in haplotype frequencies over time, it is perhaps more 
probable that Hap1_A and 2_A were present in the patient’s first sample but not detected. This 
would support within host evolution of these three closely related strains, for one of which, 
Hap3_A, there is no evidence of circulation in the population.  
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Discussion 
 
Our comparative analysis of longitudinal samples from remdesivir-treated and untreated 
patients infected with SARs-CoV-2 identifies evidence of remdesivir-associated suppression 
of viral RNA and sgRNA in vivo and uncovers the presence of mixed viral haplotypes likely 
to have evolved within each host early in infection, persisting thereafter, in some cases possibly 
within discrete tissue compartments in the lung. 
 
Suppression of viral replication is a recognised goal of SARS-CoV-2 treatment, since better 
clinical outcomes have been associated with lower viral loads (14,45). While several drugs 
with in vitro activity against SARS-CoV-2 have been identified, only remdesivir has shown 
any clinical promise(10). However, reports of its efficacy are mixed (3,7–9,11) and only one 
other report of it having an effect on viral replication in vivo has been described (46). We show 
evidence of clinical improvement in all three patients whilst on remdesivir. In patient D clinical 
improvement was associated with a fall in viral RNA levels within two days of starting 
remdesivir. Viral RNA remained undetectable until treatment was stopped, when it again rose. 
In patient A no change in viral RNA levels occurred during remdesivir treatment, however, 
SARS-CoV-2 sgRNA levels appear to have been reduced, increasing again following cessation 
of treatment (figure 4). sgRNA levels have been shown to have a weak association with viral 
replication in in vitro culture (47), however the extent to which sgRNA levels, mainly of the E 
gene which are most often measured, reflect viable virus better than viral RNA remains 
controversial (35). Overall, for samples obtained during remdesivir therapy we observe lower 
sgRNA levels even in the presence of high viral RNA (figure 4). These samples have good 
coverage and MRDs (supplementary table 1), thus excluding RNA degradation (32). Our 
results mirror findings from the macaque model wherein animals are treated with remdesivir 
12 hours following infection with SARS-CoV-2. In this model the viability in in vitro culture 
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of virus from upper respiratory samples is decreased and clinical scores are improved, despite 
no change in viral RNA levels (48). The possibility that sgRNA, may, together with viral load, 
provide a biomarker of response to remdesivir should now be explored. 
We have previously used deep sequencing and evolutionary modelling of influenza and 
norovirus genomes to gain insight into the in vivo action and efficacy of ribavirin and 
favipiravir, drugs with similar modes of action to remdesivir (13,29). Using a similar approach, 
we show considerable variation in the consensus SARS-CoV-2 sequences obtained from four 
of the nine patients, which appears unrelated to remdesivir treatment. The heterogeneity is 
explained by the presence of between 2-4 stable viral haplotypes that vary in abundance 
(figures 4A). From this we see that, while remdesivir suppressed viral replication in patient D, 
the same dose had little impact on the viral RNA from the identical strain, Hap1_A, in patient 
A (figure 4B). Remdesivir resistance was not found to account for the difference in response. 
Instead, the variable abundance of multiple distinct haplotypes present in different samples 
from patients A, B, H, and I, including in samples obtained from deep within the lung, is 
consistent with the presence of tissue compartmentalisation, wherein a pathogen replicates in 
physically separated niches within the lung potentially accumulating mutations that allow 
different populations to be distinguished. Diagnostic specimens that incompletely sample these 
poorly mixed virus populations, result in mixed haplotypes that vary in frequency from sample-
to-sample, as demonstrated in our patient data. The findings are supported by the independent 
finding that SARS-CoV-2 viral loads vary in different areas of lung sampled post mortem (49).  
Tissue compartmentalisation is well described for other inflammatory lung infections including 
Mycobacterium tuberculosis (M.tb) and influenza and has been associated with uneven drug 
penetration, leading to poor resolution of infection and predisposing to drug resistance 
(29,50,51). Modelling of drug levels within lung tissue from SARS-CoV-2 infected patients 
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suggests that remdesivir penetration into lung tissue is poor (52). In patient A, the persistence 
of different viral populations at variable frequencies including in bronchoalveolar lavage 
material supports the presence of viral compartmentalisation. Other patients may also have had 
tissue compartmentalisation but, in the absence of distinct viral populations, this could not be 
detected. Another possibility is that the effective remdesivir dose was too low, for example in 
patient G who was obese (table 1) or that duration of treatment too short, as in patients A and 
D in whom viral sgRNA and RNA respectively rebounded at the end of treatment (figures 1 
and 3A). Clearance of remdesivir metabolites is affected by renal function (53). Neonates, such 
as patient D, are known to have relatively reduced renal clearance of drugs; accumulation of 
metabolites may therefore have contributed to viral RNA suppression in patient D (54). Poor 
drug penetration into infected lung tissue has clearly been demonstrated to underlie suboptimal 
responses to treatment of M.tb infections (50,51) and tissue compartmentalisation is recognised 
to contribute to the emergence of drug resistance in both Mtb and Influenza (12,50). For both 
M.tb and Influenza, combination therapies have been shown to achieve better pathogen 
clearance from lung and clinical outcomes than single agents (50,55). 
High fidelity deep sequencing of multiple samples from the same patient together with 
computational methods that discard poorly supported MVAs minimised the contribution of 
artefact for the interpretation of within-host diversity in our sample set (17,38). Many of the 
persistent MVAs were present in early samples. As seen in other RNA viruses MVAs in SARS-
CoV-2 may be more common in patients with primary or secondary immunodeficiency 
(13,29); we did not see the accumulation of mutations over time that characterises, for example, 
norovirus infections in the immunocompromised (supplementary figures 5 and 6). Haplotypes 
occurring within an individual were phylogenetically sister taxa, with generally only one 
haplotype per patient identical to freely circulating lineages (supplementary figure 9). Many 
circulating SARS-CoV-2 lineages differ by similar numbers (one to two) of SNPs as the 
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haplotypes found within our patients, making it possible that the latter were in fact independent 
strains that were too rare to have been previously sampled. Such strains would have to have 
been acquired through co–transmission or superinfection. Although this is possible for patient 
A, on balance the data do not support this. Another possibility is that mixed haplotypes 
represent co-transmission of different strains (56). To explore the likelihood of this scenario, 
we used a large, independent and well curated data set of 318 geographically co-located SARS-
CoV-2 sequences. We show that sequences that were phylogenetically closer did not share 
more MVAs (supplementary figure 10), suggesting the co-transmission of infections is 
unlikely. The result was not changed by excluding strains sharing single MVAs which are the 
most likely to be artefact. Analysis of four randomly chosen samples with multiple well 
supported MVAs at levels of 15-85% (optimal for haplotype reconstruction), generated 
identical findings to those of our patients, namely sister taxa within hosts with only one viral 
sequence per patient found among freely circulating lineages. We conclude that early within-
host evolution most logically explains the diversity seen in patients A, B, H, and I. Within 
evolution of stable viral haplotypes (clones) is well described for norovirus and influenza in 
immunocompromised patients (57,58) Patients B, H and I were known to be 
immunocompromised, while Patient A remains under investigation for immune dysfunction. 
In contrast none of the four adult patients with mixed haplotypes from the independent cohort, 
were classified as immunocompromised (data not shown). More extensive analysis to 
understand better the frequency with which within-host variants evolve, why they arise in some 
patients and not others and whether there are any correlations with underlying clinical 
condition or outcomes is ongoing.  
A major caveat to our findings is that our cohort is paediatric, for which both the clinical picture 
and outcome of SARS-CoV-2 infections are known to differ from adults. Notwithstanding, 
similar patterns of clinical and virological response to remdesivir have been described in adults 
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(3,10,46,59). Moreover, both clinical and viral sequence data from the use of repurposed drugs 
to treat other severe RNA viral infections has shown similarities in adults and children 
(12,50,55). Larger studies using deep clinical and viral profiling of multiple samples from adult 
patients treated with remdesivir alone and in combination would provide better insight. 
In summary, we show that treatment with remdesivir is capable of reducing SARS-CoV-2 viral 
and subgenomic RNA in vivo and demonstrate that the latter, in particular, needs further 
investigation as a potential biomarker for monitoring antiviral therapy. Our data suggest that 
heterogeneous response to remdesivir is likely in many cases to be due to non-viral factors 
including, potentially, inadequate dosing and duration of treatment. The patterns of SARS-
CoV-2 within–host genetic heterogeneity uncovered by deep sequencing may be most 
parsimoniously explained by viral compartmentalisation within lung-tissue, a factor that is 
already known to impede drug penetration in patients with other lung infections. This may 
compound inherently poor remdesivir tissue penetration and rapid clearance of active 
metabolites in those with normal renal function. We and others have shown that where 
compartmentalisation occurs in influenza (29) and M. tuberculosis (50), combination therapies 
improve outcomes. Based on our experience of using similar drugs for the treatment of serious 
RNA viral infections, we propose that a more personalised medicine approach combining in 
vitro and in vivo pharmacokinetic measurements, viral RNA and sgRNA profiling together 
with viral evolutionary modelling is likely to yield important insights into the optimal use of 
remdesivir both alone and in combination for treatment of SARS-CoV-2. Finally, our data 
point to the presence of mixed genotypes in a subset of patients, which are most likely 
explained by within-host evolution rather than co-transmission. 
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Materials and Methods 
Study Cohort and approval 
We sequenced SARS-CoV-2 samples routinely collected for clinical monitoring from children 
hospitalized for COVID-19 between early March and mid-May 2020. This study was approved 
by Great Ormond Street Hospital (Clinical Audit Number #2857) and PHE Research Ethics 
and Governance Group (REGG) (R&D NR0195). 
 
Sample Collection and Viral Sequencing 
Nasopharyngeal swab samples were collected and tested for SARS-CoV-2. Full length SARS-
CoV-2 genome sequences were obtained from all positive samples using SureSelectXT target 
enrichment and Illumina sequencing. Reads generated were trimmed with trim galore (60). 
Duplicated reads were removed using Picard (61). For each patient, a unique patient reference 
was generated by mapping the remaining reads of the first sample to the SARS-CoV-2 
reference genome (NC_045512) from GenBank using bwa-mem (62). The mapping quality 
was checked using Qualimap and the consensus whole genome sequence was generated using 
QUASR (63,64). Reads from the subsequent samples of the same patient were mapped to this 
patient reference. Consensus sequences were aligned using MAFFT (65). Only genomes with 
more than 80 percent genome coverage and a mean read depth of 100 or above were included 
in downstream analysis. Seqtk was used to subsample the reads for normalisation (66). 
 
Phylogenetic Analysis 
Maximum Likelihood tree of the alignment was constructed using RAxML (67), with the GTR 
model and 1000 bootstrap replicates. All trees were rooted on the SARS-CoV-2 reference 
genome NC_045512.  
Analysis and figure generation 
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Analysis was completed in R 3.6.1 using Rstudio 1.2 (68,69). In general data was processed 
using dplyr (v0.8.3), figures were generated using ggplot2 (v3.3.1), both part of the tidyverse 
family of packages (v1.2.1) (70). We employed the fisher.test in R to compare the count-data 
of mutations for treated and untreated samples across all individuals(68). The Mann-Whitney-
Wilcoxon Test was implemented using the wilcox.test in R (68). We used Pearson’s and 
Spearman’s rank correlation for correlation analysis. This was done using the lm.test and 
cor.test function in the stats package in R (68). 
 
Haplotype Reconstruction 
Haplotypes were reconstructed using HAplotype Reconstruction Of Longitudinal Deep 
Sequences (HaROLD) with default settings (38). HaROLD does not statistically support 
haplotypes where from a single MVA, we therefore constructed by hand the haplotypes for 
Patient B. In this case the haplotype frequency was taken to be that of the single MVA. 
 
Quantification of subgenomic RNA  
We employed Periscope to detect subgenomic RNA (sgRNA) (32). sgRNA is identified based 
on the detection of the leader sequence at the 5’end (5’-
AACCAACTTTCGATCTCTTGTAGATCTGTTCT-3’) of the sequence.  
 
Minority Variant Calling 
Minority allele variants had to have a frequency of above 2% and with a minimum of 4 
supporting reads identified at sites with a read depth of ≥ 5 using VarScan (71).Transient 
MAVs, which occurred at one timepoint in an individual were discarded from the analysis. 
 
Glasgow COG-UK Sequencing and Sample Selection for haplotype reconstruction 
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Minority variants as described above, were called for 318 sequences from Glasgow in the 
COG-UK from samples collected between 28/02/2020 and 29/04/2020. Following extraction, 
samples were DNase treated (AM2222) and the libraries were prepared utilising the protocols 
developed by the ARTIC network (https://artic.network/ncov-2019). Amplicons were 
generated using either primer sets v1, v2 and v3. The DNA amplicon fragments were cleaned 
using AMPURE beads (Beckman Coulter) and 40 ng was used to prepare the Illumina 
sequencing libraries with a DNA KAPA library preparation kit (Roche). Indexing was carried 
out with NEBNext multiplex oligos (NEB) with 7 cycles of PCR. Libraries were pooled in 
equimolar amounts and loaded on a MiSeqV2 cartridge (500 cycles). In the case of CR111, the 
library was sequenced on Illumina’s NextSeq 550 System (Illumina, Part Number SY-415-
1002).  
To optimise the performance of HaROLD we selected samples with mean read depths of >500 
and SNVs occurring at frequencies of >15% with both alleles supported by >100 reads. The 
number of MVAs was tallied for all samples, and those that reported numbers in the top 2% of 
all samples were carried forward for analysis by Harold.  
 
Structural Biology 
The structure of the spike protein PDB 6XR8 was visualised using VMD (72,73). Mutations 
were modelled using Swissmodel (74,75). 
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Supplementary Materials 
Supplementary Tables 
1. Supplementary Table 1: Sequencing Metrics. 
2. Supplementary Table 2: Summary of consensus level mutations in patients A, H, and I. 
3. Summary of variants detected in all patients. 
Supplementary Figures 
1. Supplementary Figure 1: Patient timeline overview 
2. Supplementary Figure 2: Ct trajectories of 9 patients for all samples collected. 
3. Supplementary Figure 3: Clinical markers for 9 patients.  
4. Supplementary Figure 4: The P812L mutation does not affect the structure of the SARs-CoV-
2 spike protein. 
5. Supplementary Figure 5: Mutagenic signature for each patient over time. 
6. Supplementary Figure 6: Mutational burden over time in each patient. 
7. Supplementary Figure 7: Comparison of sgRNA reads per 100,000 mapped reads 
(sgRPHT) in treated and untreated individuals. 
8. Supplementary Figure 8: Polymorphisms trajectories for each patient. 
9. Supplementary Figure 9: Comparison of haplotypes from patient A , B, H and I and 
consensus of C, D, E, G with global sequences.  
10. Supplementary Figure 10: Scatter plot of shared polymorphisms (or MVAs) vs pairwise 
distance for 318 from Glasgow collected between 28/02/2020 and 29/04/2020. 
11. Supplementary figure 11: Frequency of identified haplotypes from 4/6 Glasgow 
samples processed through Harold.  
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Table 1: Overview of patient clinical, treatment, sampling and viral lineage data for all 9 patients. 
 





Diagnosis Immune Status Health 
Care 
Associated 
Days from first 
recorded 
















3 Y [8] 12 9 B.1.1 (76–78) 
B Female 6-10 Asian 25.7 severe chronic illness 
including kidney disease 
Immunocompromised 
 
Unknown N 0 3 B.1.1 (76–78) 
C Male  6-10 Black 
African 




0 N 0 5 B.2.1 (76–78) 
D Male  0-1 White 1.98 ex 32 week prematurity, 




1 Y [10] 22 7 B.1.1 (76–79) 
E Male  2-5 Other 12.4 Neuroblastoma on 
chemotherapy 
Immunocompromised Suspected 1 N 0 5 B.1.p16 (76–78) 
F Male  0-1 Unspecified 7.4 extreme prematurity, 
short gut, chronic lung 
disease 
Likely immunocompromised Suspected 0 N 0 2 B.2.1 (76–78) 
G Male  11-15 Unspecified 120 obese Immunocompetent 
 
10 Y [10] 10 10 B.1.1.7 (76–78) 
H Male  0-1 Black 
African 
10.3 Hepatoblastoma Immunocompromised 
 
Unknown N 34 13 B.1.p11 (76–78) 
I Female 0-1 Unspecified 9.85 PNET, on chemotherapy  Immunocomrpromised Suspected Asymptomatic N 0 2 B.1.p16 (76–78) 
All rights reserved. No reuse allowed without permission. 
perpetuity. 
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 
The copyright holder for thisthis version posted November 20, 2020. ; https://doi.org/10.1101/2020.11.18.20230599doi: medRxiv preprint 
Figure 1. Ct trajectories of 9 patients from first day up to 40 days post first positive. One panel 
per patient, red line indicates remdesivir received, black dot is sample taken, blue circle 
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Figure 2: RAxML phylogenetic trees rooted at NC_045512. A) Tree using consensus level 
sequences for Patients A-I. Boxes highlight distinct, identical sequences excluding gaps, found 
in patients A, H and I over time. Samples are labelled as [Patient][Time]. B) Tree using 
haplotype sequences for Patients A, B, H, and I and consensus levels sequences for Patients D-
G for which no haplotypes are identified. Haplotypes defining mutations are shown along the 
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Figure 3: Evaluation of effect of remdesivir on levels of sgRPHT. A) Comparison of ct values 
and sgRPHT over time by Patient. Stacked bars represent sgRPHT values coloured by gene. 
Black line represent ct values, with blue circles annotating successfully sequenced samples. Y-
axis is days post first positive. B) Box-plot of sgRPHT on and off remdesivir for patients A 
and G. Samples from each individual are identified by their shape. Treated samples have low 
sgRPHT than untreated samples taken in the same time-window post first positive (Mann-
Whitney-Wilcoxon test, p = 0.05). Patient D was excluded from this comparison as no 
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Figure 4: Frequency of identified haplotype over time for individual patients. A) Haplotype 
frequency over time for patients A, B, H and I. B) right: Phylogenetic tree of haplotypes from 
patients A and D, nucleotide mutation shown above each cluster left: Haplotype frequency over 
time for patients A and D. Black line is Ct value, red line indicates remdesivir received, black 
dot is sample taken, blue circle indicates sample successfully sequenced. Bars indicate 
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